Relmada Therapeutics (RLMD) Non-Current Debt (2014 - 2019)
Relmada Therapeutics' (RLMD) quarterly Non-Current Debt came in at $110200.0 in Q4 2019, down 3.92% year-on-year from $114700.0 in Q4 2018, and down 56.94% on a QoQ basis from $255900.0 in Q3 2019.
Relmada Therapeutics (RLMD) Non-Current Debt (2014 - 2019) Analysis & Trends
Relmada Therapeutics (RLMD) has 6 years of Non-Current Debt data on file, last reported at $110200.0 in Q4 2019.
- On a quarterly basis, Non-Current Debt fell 3.92% year-over-year to $110200.0 in Q4 2019; TTM through Dec 2019 was $110200.0, a 3.92% decrease from a year earlier, with the FY2019 full-year figure at $110200.0, changed N/A from the prior year.
- Non-Current Debt for Q4 2019 stood at $110200.0, down from $255900.0 in the prior quarter.
- Over the last five years, Non-Current Debt for RLMD reached as high as $3.2 million in Q3 2018 and fell as low as $27600.0 in Q1 2017.
- Historically, Non-Current Debt has averaged $428753.1 across 5 years, with a median of $216150.0 in 2015.
- Across the five-year window, Non-Current Debt jumped 1061.55% in 2017 and slumped 91.99% in 2019, its largest moves.
- Year by year, Non-Current Debt stood at $88500.0 in 2015, then gained by 24.29% to $110000.0 in 2016, then soared by 1061.55% to $1.3 million in 2017, then tumbled by 91.02% to $114700.0 in 2018, then declined by 3.92% to $110200.0 in 2019.
- Per Business Quant data, the three most recent Non-Current Debt figures were $110200.0 in Q4 2019, $255900.0 in Q3 2019, and $364200.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Relmada Therapeutics | 205.29 Mn | 205.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 110,200.00 |
| Sep 30, 2019 | 255,900.00 |
| Jun 30, 2019 | 364,200.00 |
| Mar 31, 2019 | 28,800.00 |
| Dec 31, 2018 | 114,700.00 |
| Sep 30, 2018 | 3.19 Mn |
| Jun 30, 2018 | 285,200.00 |
| Mar 31, 2018 | 27,900.00 |
| Dec 31, 2017 | 1.28 Mn |
| Sep 30, 2017 | 678,875.00 |
| Jun 30, 2017 | 276,700.00 |
| Mar 31, 2017 | 27,600.00 |
| Dec 31, 2016 | 110,000.00 |
| Sep 30, 2016 | 164,400.00 |
| Jun 30, 2016 | 273,700.00 |
| Dec 31, 2015 | 88,500.00 |
| Sep 30, 2015 | 176,400.00 |
| Jun 30, 2015 | 263,800.00 |
| Jun 30, 2014 | 58,400.00 |